Elisa Agostinetto: The practice-changing results of the HypoG-01 UNICANCER trial at ESMO24

Elisa Agostinetto shared a post by MediMix, on X, adding:

”At ESMO24 the practice-changing results of the HypoG-01 UNICANCER trial were presented, showing that hypofractionated radiotherapy in early breast cancer is non-inferior to normofractionated radiotherapy and should be standard of care. I had the privilege to discuss these results with Dr. Sofia Rivera.”

Quoting MediMix‘s post:

”Presidential Highlight from ESMO2024! Dr. Elisa Agostinetto and Dr. Sofia Rivera share key results from the HypoG-01 trial, showing hypofractionated radiotherapy reduces treatment time without increasing toxicity.”

View attached video.
Source: Elisa Agostinetto/X and MediMix/X

Elisa Agostinetto, is a medical oncologist, specializing in breast cancer research. Elisa Agostinetto is a Medical Research Fellow at the University Hospital of Brussels since November 2021. Additionally, she has serves as a Clinical Research Fellow at Jules Bordet Institute. Her work focuses on clinical research in oncology, likely involving various aspects of cancer treatment and patient care. Actively engaged in professional societies like ESMO, ASCO, and BSMO, she also contributes as a young investigator in the EORTC Breast Cancer Working Group and as a Committee member of the Young Cancer Professionals within the European Cancer Organization.